Vanderbilt Multidisciplinary Clinical Research Center

范德比尔特多学科临床研究中心

• 批准号: 8327311
• 负责人: Charles M. Stein
• 金额: $ 122.8万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-18 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8327311
• 关键词: Address; Advisory Committees; Antirheumatic Agents; Cardiovascular Diseases; Clinical; Clinical Research; Collection; Communication; Data Analyses; Degenerative polyarthritis; Development; Diabetes Mellitus; Disease; Doctor of Philosophy; Ensure; Environment; Epidemiology; Fostering; Growth; Health; Hyperinsulinism; Infection; Inflammation; Lupus; Lymphoma; Methodology; Mission; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Outcome; Patients; Pharmacoepidemiology; Pioglitazone; Pregnancy; Research; Research Methodology; Research Personnel; Research Project Grants; Resources; Rheumatism; Rheumatoid Arthritis; Risk; Strategic Planning; Techniques; Training; Universities; base; design; multidisciplinary; new growth; programs; success; training project

The Specific Aims of the Vanderbilt University Multidisciplinary Clinical Research Center (VMCRC) are: 1) To pursue a multidisciplinary clinical research scientific program that will alter the outcomes of patients with rheumatic diseases. 2) To promote and foster multidisciplinary clinical research in rheumatic diseases by leveraging institutional training and research resources and the extensive research base that supports the VMCRC and facilitate growth of new projects and the training of new investigators. The VMCRC (Director: C. Michael Stein MD; Associate Director: Wayne Ray PhD) is comprised of three clinical research projects centered around a Methodology Core that serves all projects. The three projects span a range of clinical research approaches (CRC clinical research, pharmacoepidemiology, health outcomes) and diverse rheumatic diseases (rheumatoid arthritis, lupus, osteoarthritis) central to the mission of NIAMS. Project 1 (Stein) is a clinical research/CRC proof-of-concept study using pioglitazone to define the relationships between hyperinsulinemia, disease activity and inflammation in patients with rheumatoid arthritis. Project 2 (Griffin) studies the effect of newer disease modifying anti-rheumatic drugs on the long-term outcomes of cardiovascular disease, diabetes, infection and lymphoma. Project 3 (Cooper) uses a unique local pharmaco-epidemiologic resources to address the risks of anti-rheumatic drugs administered during pregnancy. A common Methodology Core (Arbogast) provides support for the design, collection and analysis of data, and the development of new techniques for improvement of the research methodology used. An Executive Committee and an External Advisory Committee will assist in scientific direction, strategic planning and the leveraging of VMCRC and institutional resources to greatest effect. An Administrative Unit will ensure responsible, efficient conduct of research, seamless communication, fiscal efficiency and thoughtful prioritization of resources. In summary, the VMCRC brings together talented multidisciplinary clinical researchers with a track record in performing collaborative research, fostering new research and facilitating the growth of trainees. The VMCRC is situated in an environment that provides an extraordinarily rich research base as well as outstanding institutional resources and a commitment to clinical research that will facilitate success of the Center.

范德比尔特大学多学科临床研究中心（VMCRC）的具体目标是：1)开展多学科临床研究科学项目，以改变风湿病患者的预后。2)利用机构培训和研究资源以及支持VMCRC的广泛研究基础，促进和促进风湿病多学科临床研究，促进新项目的发展和新研究者的培训。VMCRC（主任：C. Michael Stein医学博士；副主任：Wayne Ray博士）由三个临床研究项目组成，这些项目围绕一个方法论核心，为所有项目服务。这三个项目涵盖了一系列临床研究方法（CRC临床研究、药物流行病学、健康结果）和各种风湿性疾病（类风湿关节炎、狼疮、骨关节炎），这是NIAMS的核心任务。Project 1 （Stein）是一项临床研究/CRC概念验证研究，使用吡格列酮来确定类风湿关节炎患者高胰岛素血症、疾病活动性和炎症之间的关系。项目2 （Griffin）研究了新型疾病修饰抗风湿药物对心血管疾病、糖尿病、感染和淋巴瘤长期预后的影响。项目3（库珀）利用当地独特的药物流行病学资源来解决妊娠期间使用抗风湿药的风险。通用方法论核心（Arbogast）为数据的设计、收集和分析提供支持，并为改进所使用的研究方法开发新技术。一个执行委员会和一个外部咨询委员会将协助科学指导、战略规划以及最大限度地利用VMCRC和机构资源。行政单位将确保负责、有效地进行研究、无缝沟通、财政效率和考虑周到的资源优先次序。总之，VMCRC汇集了有才华的多学科临床研究人员，他们在开展合作研究、促进新研究和促进学员成长方面有着良好的记录。VMCRC所处的环境提供了非常丰富的研究基础，以及优秀的机构资源和对临床研究的承诺，这将促进中心的成功。

项目成果

Development of an algorithm to identify serious opioid toxicity in children.

• DOI: 10.1186/s13104-015-1185-x
• 发表时间: 2015-07-04
• 期刊: BMC research notes
• 影响因子: 1.8
• 作者: Chung, Cecilia P;Callahan, S Todd;Ray, Wayne A
• 通讯作者: Ray, Wayne A

Effects of anti-tumor necrosis factor α agents on bone.

• DOI: 10.1097/bor.0b013e328356d212
• 发表时间: 2012-09
• 期刊: Current opinion in rheumatology
• 影响因子: 5.1
• 作者: Kawai VK;Stein CM;Perrien DS;Griffin MR
• 通讯作者: Griffin MR

Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission.

坚持使用缓解疾病的抗风湿药物以及暴露错误分类对入院风险的影响。

• DOI: 10.1002/acr.20087
• 发表时间: 2010
• 期刊: Arthritis care & research
• 影响因子: 4.7
• 作者: Grijalva,CarlosG;Kaltenbach,Lisa;Arbogast,PatrickG;MitchelJr,EdwardF;Griffin,MarieR
• 通讯作者: Griffin,MarieR

Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study.

• DOI: 10.1002/art.39462
• 发表时间: 2016-02
• 期刊: Arthritis & rheumatology (Hoboken, N.J.)
• 作者: Wiese AD;Griffin MR;Stein CM;Mitchel EF Jr;Grijalva CG
• 通讯作者: Grijalva CG

Reweighted Mahalanobis distance matching for cluster-randomized trials with missing data.

• DOI: 10.1002/pds.3260
• 发表时间: 2012-05
• 期刊: Pharmacoepidemiology and drug safety
• 影响因子: 2.6
• 作者: Greevy RA Jr;Grijalva CG;Roumie CL;Beck C;Hung AM;Murff HJ;Liu X;Griffin MR
• 通讯作者: Griffin MR